公开(公告)号：US20250066361A1

公开(公告)日：2025-02-27

申请号：US18943115

申请日：2024-11-11

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： John G. CATALANO ,  Pek Yoke Chong ,  Hamilton D. Dickson ,  Martin R. Leivers ,  Jason Gordon Weatherhead

IPC: C07D471/14 ,  A61P31/20

Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.

公开(公告)号：US20250057849A1

公开(公告)日：2025-02-20

申请号：US18723227

申请日：2022-12-22

Applicant: CJ CheilJedang Corporation

Inventor： Ho Jin MOON ,  Young Nam KIM ,  Na-Ra LEE ,  Changsuk LEE ,  Ah Reum CHO

IPC: A61K31/522 ,  A23K20/137 ,  A61P31/14 ,  A61P31/16 ,  A61P31/20

Abstract: The present application relates to an antiviral composition comprising nucleoside analogues derived from a nucleotide, and a composition, a feed or a feed additive for enhancing immunity.

公开(公告)号：US12208093B2

公开(公告)日：2025-01-28

申请号：US17669425

申请日：2022-02-11

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

Inventor： Ravit Boger ,  Marc Ferrer ,  Juan Marugan ,  Andres Dulcey Garcia ,  Noel Terrence Southall ,  Xin Hu

IPC: A61K31/4745 ,  A61K31/522 ,  A61K31/662 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/05 ,  A61K45/06 ,  A61P31/20 ,  A61P31/22 ,  A61K9/00

Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

公开(公告)号：US12202862B2

公开(公告)日：2025-01-21

申请号：US18452698

申请日：2023-08-21

Applicant: MELBOURNE HEALTH

Inventor： Renae Walsh ,  Stephen Locarnini ,  Hans Netter ,  Ronald Farquhar

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/295 ,  A61K39/385 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00

Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

公开(公告)号：US12195517B2

公开(公告)日：2025-01-14

申请号：US17280803

申请日：2019-06-12

Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD

Inventor： Jianqing Xu ,  Yang Huang ,  Xiaoyan Zhang ,  Lu Wang ,  Mingquan Gao ,  Jiahao Sun

IPC: C07K14/73 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  A61P31/04 ,  A61P31/16 ,  A61P31/20 ,  A61P31/22 ,  A61P35/00 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86

Abstract: The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.

公开(公告)号：US20240408103A1

公开(公告)日：2024-12-12

申请号：US18699027

申请日：2022-09-28

Applicant: Medience Co., Ltd.

Inventor： Soo Hyun PARK ,  Set Byeol KIM ,  Jeong Hoon KIM ,  Young Won MO

IPC: A61K31/536 ,  A61K31/138 ,  A61K31/155 ,  A61P31/14 ,  A61P31/20

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combination of efavirenz and fluoxetine is administered or a complex, mixture or combination of efavirenz fluoxetine, to which a biguanide-based compound metformin is added, is administered, antiviral efficacy against various zoonotic viruses including SARS-CoV-2 is remarkably higher than when each is administered alone, and thus efavirenz and fluoxetine, in addition to the biguanide-based compound, can be effectively used as active ingredients of a composition for preventing or treating viral infectious diseases.

公开(公告)号：US12161625B2

公开(公告)日：2024-12-10

申请号：US18059806

申请日：2022-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20 ,  C07D487/04 ,  C07D519/00

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20240384294A1

公开(公告)日：2024-11-21

申请号：US18624863

申请日：2024-04-02

Applicant: University of Iowa Research Foundation ,  University of Kansas

Inventor： Ziying Yan ,  John F. Engelhardt ,  Jianming Qiu ,  Zekun Wang

IPC: C12N15/86 ,  A61K39/00 ,  A61K39/23 ,  A61P31/20 ,  C12N7/00

Abstract: Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.

公开(公告)号：US20240382583A1

公开(公告)日：2024-11-21

申请号：US18609504

申请日：2024-03-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

公开(公告)号：US20240382514A1

公开(公告)日：2024-11-21

申请号：US18780176

申请日：2024-07-22

Applicant: Suzhou Ribo Life Science Co., Ltd.

Inventor： Hongyan ZHANG ,  Shan GAO ,  Daiwu KANG

IPC: A61K31/713 ,  A61K47/54 ,  A61P31/20

Abstract: Provided are a siRNA for inhibiting the expression of hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified nucleotide. The siRNA includes a sense strand and an antisense strand. The sense strand of the siRNA includes a nucleotide sequence 1 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 155, and the antisense strand of the siRNA includes a nucleotide sequence 2 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 156.